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Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 1 
gluten 2 
Abstract 3 
Opioid like morphine and codeine are used for the management of pain, but are associated 4 
with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 5 
presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 6 
peptides were identified and occurrence of predicted sequences or their structural motifs were 7 
analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 8 
ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 9 
activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 10 
production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 11 
mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ-12 
opioid receptor, respectively. The study showed that in silico approach can be used for the 13 
prediction of opioid peptides from gluten. 14 
Keywords: opioid, tyrosine, proline, in-silico, BIOPEP, peptides, peptide ranking 15 
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1 Introduction 17 
Opioids, such as morphine and codeine, are the most common clinically used drugs for pain 18 
management (Janecka, Fichna, & Janecki, 2004; Teschemacher, 2003; Trescot, Datta, Lee, & 19 
Hansen, 2008). These opioids bind to opioid receptors present in the central and peripheral 20 
nervous system. However, they are often associated with side-effects like sedation, dizziness, 21 
nausea, vomiting, constipation, addiction, tolerance and respiratory depression (Benyamin et 22 
al., 2008). Opioids were considered to be alkaloid (derived from opium) only until discovery 23 
of endogenous opioid peptides in 1975 (Goldstein, Goldstein, & Cox, 1975; Hughes et al., 24 
1975). These endogenous peptides and their modified forms have shown activity similar to 25 
alkaloids (Giordano et al., 2010; Mollica et al., 2014; Mollica et al., 2005; Mollica et al., 26 
2013b; Mollica et al., 2011). However, exogenous opioid peptides or exorphins are naturally 27 
derived from food proteins (Stefanucci et al., 2016; Yoshikawa, 2013). These exogenous 28 
peptides are of particular interest as they are naturally derived from food, have possibly less 29 
side-effects (compared to synthetic drugs) and are inexpensive to produce (Garg, Nurgali, & 30 
Mishra, 2016; Udenigwe, Gong, & Wu, 2013). Most known bioactive peptides are small and 31 
non-immunogenic, as compared to larger peptides (6-25 amino acids) (Wang, Mejia, & 32 
Gonzalez, 2005). Hence, small peptides are researched more for their bioactivity and 33 
considered safe (Shahidi & Zhong, 2008). 34 
Generally, bioactive peptides, including opioids, are produced by hydrolysis of food protein 35 
during food processing (ripening, fermentation), storage (Choi, Sabikhi, Hassan, & Anand, 36 
2012) and during gastrointestinal (GI) digestion (Garg et al., 2016; Stefanucci et al., 2016). 37 
The protein hydrolysate is then tested for bioactivity using in vitro and in vivo methods. Since 38 
these hydrolysates are mixtures of several peptides, their bioactivity results from the additive 39 
and synergistic effect of various components present. Bioactive hydrolysates containing 40 
mixtures of peptide needs to be fractionated, purified and then tested for bioactivity 41 
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(Udenigwe & Aluko, 2012). The whole process of preparing bioactive peptides from native 42 
proteins by hydrolysis, separation and fractionation, is tedious, time consuming and the yields 43 
are low (Udenigwe, 2014), limiting and/or delaying their use in clinical applications. 44 
Alternatively, bioinformatics tools can be used for predicting the presence of bioactive 45 
peptides in proteins (in silico approach) (Carrasco-Castilla, Hernández-Álvarez, Jiménez-46 
Martínez, Gutiérrez-López, & Dávila-Ortiz, 2012; Holton, Pollastri, Shields, & Mooney, 47 
2013; Lacroix & Li-Chan, 2012). Using this approach, one can search for potential precursors 48 
of bioactive peptides and develop efficient proteolytic enzymes for their release from native 49 
protein sequences (Carrasco-Castilla et al., 2012; Udenigwe et al., 2013). In this approach, 50 
protein databases, such as, UniProtKB, SwissProt and TrEMBL can be used to access 51 
sequences of a food protein, and presence of bioactive peptides can be predicted using 52 
peptide databases BIOPEP and Pepbank (Udenigwe, 2014). The BIOPEP application 53 
contains a database of biologically active peptide sequences and a program enabling 54 
construction of profiles of the potential biological activity of protein fragments, calculation of 55 
quantitative descriptors as measures of the value of proteins as potential precursors of 56 
bioactive peptides, and prediction of bonds susceptible to hydrolysis by endopeptidases in a 57 
protein (Minkiewicz, Dziuba, Iwaniak, Dziuba, & Darewicz, 2008). In fact, it has been 58 
successfully used for prediction of bioactive peptides from different food proteins having 59 
angiotensin converting enzyme inhibitory (ACE-I) activity (Cheung, Nakayama, Hsu, 60 
Samaranayaka, & Li-Chan, 2009; Dellafiora et al., 2015) and dipeptidyl peptidase-IV 61 
inhibitors (DPP-IV) (Lacroix & Li-Chan, 2012; Nongonierma, Mooney, Shields, & 62 
FitzGerald, 2014). PeptideRanker is a web based application and can predict the probability 63 
of a peptide being bioactive according to their score between 0 and 1 and can assist in the 64 
discovery of new bioactive peptides across many functional classes. Generally, any peptide 65 
over 0.5 threshold is labelled to be bioactive (Mooney, Haslam, Holton, Pollastri, & Shields, 66 
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2013; Mooney, Haslam, Pollastri, & Shields, 2012). Increasing the threshold from 0.5 to 0.8 67 
reduces the number of false positive prediction from 16 to 6 %, however, true positive rates 68 
also decrease (Mooney et al., 2012). If predicted probability is close to 1, the probability of 69 
peptide to be bioactive is significantly high (Mooney et al., 2012).  70 
Bioinformatics approach is used for identification of structural patterns of peptides of known 71 
bioactivities. Presence of tryptophan in a peptide is associated with antioxidant activity 72 
(Chuan-Hsiao, Yin-Shiou, Shyr-Yi, & Wen-Chi, 2014) and carboxyl terminal alanine or 73 
proline containing peptides are DPP-IV inhibitors (Lacroix & Li-Chan, 2012). However, 74 
there is general lack of information for screening opioid peptides using bioinformatics 75 
approach. Wheat gluten contains exorphins; A5, A4, B5, B4 and C, having sequences 76 
GYYPT, GYYP, YGGW, YGGWL and YPISL, respectively (Fukudome & Yoshikawa, 77 
1992; Zioudrou, Streaty, & Klee, 1979). Most of food derived opioid peptides have tyrosine 78 
and proline residues within them (Yoshikawa, 2013). Tyrosine (Y) is present either at the 79 
amino terminal or at the second position (as in gluten exorphins GYYPT and GYYP) and acts 80 
as part of the message domain to anchor the opioid peptide within the receptor (Heyl et al., 81 
2003; Li et al., 2005). At position 1, Y acts as a dual hydrogen bond donor/acceptor with less 82 
acidic hydroxyl groups exhibiting stronger binding to opioid receptors. Moreover, steric bulk 83 
in the Y strengthens receptor binding by either a ligand conformational effect or enhanced 84 
van der Waals interactions with a loose receptor site (Heyl et al., 2003). Proline (P) acts as a 85 
spacer that fixes the peptide shape and induces other residues to assume proper spatial 86 
orientation for interacting with the opioid receptor (Cardillo, Gentilucci, Qasem, Sgarzi, & 87 
Spampinato, 2002). Peptides containing P also exhibit enhanced resistance to hydrolysis by 88 
enzymes of GI tract (Cardillo et al., 2002; Trivedi et al., 2014) and are therefore more likely 89 
to be active upon oral administration (Yang et al., 2001).  90 
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For peptides to exert opioid activity, they must bind to opioid receptors present within the 91 
central and enteric nervous systems. Opioid receptors belong to the superfamily of G protein 92 
coupled receptors (GPCRs) and on activation by opioid ligands, they inhibit adenylate 93 
cyclase enzyme (Garg et al., 2016; Gupta, Décaillot, & Devi, 2006) thus decreasing the 94 
production of cyclic adenosine monophosphate (cAMP) in the cells (Gupta et al., 2006). This 95 
decrease in concentration of cAMP in cells is used for screening opioid ligands (Huang, 96 
Kehner, Cowan, & Liu-Chen, 2001). This forms the basis of using cell lines transfected with 97 
opioid receptors for assaying the activity of peptides and using it for confirmation of peptides 98 
selected using bioinformatics approach.   99 
The objective of this study was to search for opioid peptides in wheat gluten proteins based 100 
on the presence of tyrosine and proline, and use bioinformatics tools, BIOPEP and 101 
PeptideRanker to identity and rank these peptides for likelihood of having opioid activity. 102 
The identified peptides were then assayed for opioid activity by cAMP assay for confirmation 103 
of their bioactivity. 104 
 105 
2 Materials and Methods 106 
 107 
2.1 Chemicals and reagents   108 
Cell culture media, Dulbecco's Modified Eagle's Medium (DMEM) containing 20 mM 4-(2-109 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), fetal bovine serum (FBS), 110 
antibiotic-antimycotic (100X) and hygromycin-B and phosphate buffer saline (PBS) - pH 7.2, 111 
were acquired from Life Technologies (Carlsbad, California, US). Lance cAMP detection 112 
reagents, and bovine serum albumin (BSA) stabiliser and optiplate were from Perkin Elmer 113 
Life Sciences (Cambridge, MA). 3-Isobutyl-1-methylxanthine (IBMX), trypsin-EDTA, 114 
forskolin, [D-Ala
2
, N-MePhe
4
, Gly-ol
5
]-enkephalin (DAMGO) and dynorphin A and all other 115 
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chemicals were purchased from Sigma Aldrich (Australia) unless otherwise stated. Custom 116 
peptides were synthesized from Mimotopes (Melbourne, Australia) at > 95% purity. 117 
 118 
2.2 Cell lines 119 
FlpIn CHO (Chinese hamster ovary) cells stably transfected with pOG44 vector encoding Flp 120 
recombinase and pDEST vector encoding either human µ or κ receptors were a kind gift from 121 
Dr. Meritxell Canals, Monash Institute of Pharmaceutical Sciences, Melbourne, Australia. 122 
The cells were transfected using polyethylenimine as transfection reagent and hygromycin-B 123 
(200 µg/mL) was used as a selection agent (Burford et al., 2015).  124 
 125 
2.3 In silico analysis 126 
2.3.1 Sequences of wheat gluten proteins 127 
The sequences of wheat storage proteins high molecular weight (HMW) and low molecular 128 
weight (LMW) glutenins and gliadins (alpha, gamma and omega) were accessed from 129 
UniProt database at http://www.uniprot.org/uniprot/ (Boutet, Lieberherr, Tognolli, Schneider, 130 
& Bairoch, 2007). These sequences were then searched for the presence of tri and oligo-131 
peptides containing Y and P amino acids either consecutively or separated by a single amino 132 
acid. 133 
 134 
2.3.2 Peptide ranking and bioactivity prediction 135 
Occurrence of predicted sequences or their structural motif thereof were analysed in known 136 
opioids using BIOPEP database (Minkiewicz et al., 2008). The PeptideRanker 137 
(Bioware.ucd.ie) was used to rank the predicted sequences according to bioactivity. A peptide 138 
having ranking closer to 1, increases its chances to be bioactive so they were selected to be 139 
tested for opioid activity.  140 
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2.4 Opioid activity assay 141 
Opioid activity of the peptides was determined on the basis of cAMP assay. Cells were grown 142 
and maintained at 37°C in a humidified incubator containing 5% CO2 in DMEM, 10% FBS, 143 
1% antibiotic-antimycotic and 200 µg/mL hygromycin-B (Burford et al., 2015). Cells were 144 
grown to 90% confluency, harvested and resuspended at 2x10
6 
cells/mL in the media 145 
(DMEM + FBS + hygromycin B) and 100 µL of cells were seeded into sterile 96 well plates 146 
and incubated at 37°C and 5% CO2 overnight. The culture media in all the wells were 147 
replaced with stimulation buffer consisting of PBS, 50 mM IBMX and BSA stabiliser and 148 
incubated for 30 minutes before stimulation. Cells were stimulated at different concentrations 149 
of peptides in the presence of 10 µM forskolin for 30 minutes. The stimulation buffer 150 
containing peptides was then removed and 50 µL of ice cold 100% ethanol was added to each 151 
well. Ethanol was then evaporated and 75 µL of lysis buffer (0.3% tween-20, 5 mM HEPES 152 
and 0.1 % BSA) was added to each well and the change in concentration of cAMP in the 153 
lysate was determined using Lance cAMP detection kit. 5 µL of lysate containing cAMP was 154 
mixed with 5 µL of Alexa flour-647 anti-cAMP antibody (stock antibody diluted at 1:100 in 155 
detection buffer provided in kit). Detection mix containing Europium W8044 labelled 156 
streptavidin and biotin-cAMP was prepared according to kit instructions and kept at room 157 
temperature for 15 minutes. The detection mix (10 µL) was added to each well and incubated 158 
for 1 hour before reading. Time-resolved fluorescence (TRF) was detected using an Envision 159 
plate reader (Perkin Elmer, Cambridge, MA) with excitation at 337 nm and emission read at 160 
615 nm and 665 nm. DAMGO and dynorphin A were used as positive controls for µ and κ 161 
opioid receptors, respectively. Data were analysed and EC50 values determined using 162 
nonlinear regression analysis to fit a logistic equation using Graph Pad Prism, version 7 163 
(Graph Pad San Diego, California, US). 164 
 165 
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3 Results and Discussions 166 
 167 
3.1 Prediction of opioid peptide sequences in wheat gluten 168 
Wheat is one of the most important cereals consumed globally providing protein and 169 
carbohydrates to the diet. The main storage protein of wheat gluten consists of glutenins and 170 
gliadins. Table 1 shows the sequence of gluten proteins and the relevant sequences containing 171 
Y and P are highlighted in each of the wheat proteins. Peptides sequences YPG, YPTSP, 172 
YYPG (from HMW glutenin), YIPP, YPH, YPQ, YPS (from alpha-gliadin), YPH, YVPP 173 
(from gamma gliadin) and YPN (from omega gliadin) are identified to have opioid activity 174 
(Table 1). The occurrence frequencies of these opioid peptides are 17, 7, 2 and 1 in HMW 175 
glutenin, alpha gliadin, gamma gliadin and omega gliadin, respectively. Based on this 176 
observation, HMW glutenin is by far a superior source of opioid peptides than the rest of 177 
tested proteins.  178 
 179 
Table 1. Sequence of wheat storage proteins as obtained by UniProt 180 
Wheat 
protei
n 
UniProt 
accession 
number 
Amino acid (AA) sequence  AA 
residue  
HMW 
gluteni
n 
subunit 
Q41553 MTKRLVLFAAVVVALVALTAAEGEASGQLQCEREL
QEHSLKACRQVVDQQLRDVSPECQPVGGGPVARQY
EQQVVVPPKGGSFYPGETTPPQQLQQSILWGIPALLR
RYYLSVTSPQQVSYYPGQASSQRPGQGQQEYYLTSP
QQSGQWQQPGQGQSGYYPTSPQQSGQKQPGYYPTS
PWQPEQLQQPTQGQQRQQPGQGQQLRQGQQGQQS
GQGQPRYYPTSSQQPGQLQQLAQGQQGQQPERGQQ
GQQSGQGQQLGQGQQGQQPGQKQQSGQGQQGYY
PISPQQLGQGQQSGQGQLGYYPTSPQQSGQGQSGY
YPTSAQQPGQLQQSTQEQQLGQEQQDQQSGQGRQG
815 
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QQSGQRQQDQSGQGQQPGQRQPGYYSTSPQQLGQ
GQPRYYPTSPQQPGQEQQPRQLQQPEQGQQGQQPE
QGQQGQQQRQGEQGQQPGQGQQGQQPGQGQPGY
YPTSPQQSGQGQPGYYPTSPQQSGQLQQPAQGQQP
GQEQQGQQPGQGQQPGQGQPGYYPTSPQQSGQEQ
QLEQWQQSGQGQPGHYPTSPLQPGQGQPGYYPTSP
QQIGQGQQPGQLQQPTQGQQGQQPGQGQQGQQPG
EGQQGQQPGQGQQPGQGQPGYYPTSLQQSGQGQQ
PGQWQQPGQGQPGYYPTSSLQPEQGQQGYYPTSQQ
QPGQGPQPGQWQQSGQGQQGYYPTSPQQSGQGQQ
PGQWLQPGQWLQSGYYLTSPQQLGQGQQPRQWLQ
PRQGQQGYYPTSPQQSGQGQQLGQGQQGYYPTSPQ
QSGQGQQGYDSPYHVSAEHQAASLKVAKAQQLAA
QLPAMCRLEGGDALLASQ 
LMW 
gluteni
n  
Q8W3V5 MKTFLVFALIAVVATSAIAQMETSCISGLERPWQQQPLPP
QQSFSQQPPFSQQQQQPLPQQPSFSQQQPPFSQQQPILSQQ
PPFSQQQQPVLPQQSPFSQQQQLVLPPQQQQQQLVQQQIP
IVQPSVLQQLNPCKVFLQQQCSPVAMPQRLARSQMWQQ
SSCHVMQQQCCQQLQQIPEQSRYEAIRAIIYSIILQEQQQG
FVQPQQQQPQQSGQGVSQSQQQSQQQLGQCSFQQPQQQ
LGQQPQQQQQQVLQGTFLQPHQIAHLEAVTSIALRTLPT
MCSVNVPLYSATTSVPFGVGTGVGAY 
303 
alpha-
gliadin 
A0A0E3Z527 MKTFLILALLAIVATTATIAVRVPVPQLQPQNPSQQQ
PQEQVPLMQQQQQFPGQQEQFPPQQPYPHQQPFPSQ
QPYPQPQPFPPQLPYPQTQPFPPQQPYPQPQPQYPQP
QQPISQQQAQQQQQQQQILQQILQQQLIPCRDVVLQ
QHNIAHASSQVLQQSTYQLVQQLCCQQLWQIPEQS
RCQAIHNVVHAIILHQQQQQQQQQQQQPLSQVSFQ
QPQQQYPSGQGSFQPSQQNPQAQGSVQPQQLPQFEE
IRNLALETLPAMCNVYIPPYCTIAPVGIFGTN 
284 
gamma 
gliadin 
P21292 MKTLLILTILAMATTIATANMQVDPSGQVQWPQQQPFPQ
PQQPFCQQPQRTIPQPHQTFHHQPQQTFPQPQQTYPHQPQ
QQFPQTQQPQQPFPQPQQTFPQQPQLPFPQQPQQPFPQPQ
QPQQPFPQSQQPQQPFPQPQQQFPQPQQPQQSFPQQQQPA
302 
10 
 
IQSFLQQQMNPCKNFLLQQCNHVSLVSSLVSIILPRSDCQ
VMQQQCCQQLAQIPQQLQCAAIHSVAHSIIMQQEQQQG
VPILRPLFQLAQGLGIIQPQQPAQLEGIRSLVLKTLPTMCN
VYVPPDCSTINVPYANIDAGIGGQ 
omega 
gliadin 
Q6PNA3 
 
MKPHHDGYKYTCSIIVTFHYPNFKHQDQKHQFQESIKHK
SKMKTFIIFVLLSMPMSIVIAARHLNPSDQELQSPQQQFLE
KTIISAATISTSTIFTTTTISHTPTIFPPSTTTTISPTPTTNPPTT
TMTIPLATPTTTTTFSPAPTTISLATTTTISLAPTTNSPITTT
TIPAATPETTTTIPPATRTNNYASTATTISLLTATTTPPATP
TTILSATTTTISPAPTIISPATRTNNSLATPTTIPPATATTIPP
ATRTNNSPATATTIPPAPQQRFPHTRQKFPRNPNNHSLCS
THHFPAQQPFPQQPGQIIPQQPQQPLPLQPQQPFPWQPEQ
RSSQQPQQPFSLQPQQPFS 
354 
    : predicted opioid peptide sequences  181 
 182 
3.2 Selection of opioid peptides using BIOPEP database and PeptideRanker  183 
BIOPEP is a database of biologically active peptide sequences and a tool for evaluation of 184 
proteins as the precursor of bioactive peptides. The database was used to compare the 185 
presence of structural motifs comprising of di or tripeptides in identified peptides in 186 
comparison to known opioid peptides (Table 2). The peptides were classified according to 187 
different search terms and for every sequence within the class, EC50 values are reported. YYP 188 
(part of YYPG) structural motif is present in eight opioid peptides with EC50 as low as 60 µM 189 
(gluten A5 exorphin) (Table 2). Similarly, five known opioid peptides contain structural 190 
motif IP (part of YIPP), whereas Casoxin C, containing YIP (part of YIPP) is an antagonist. 191 
YVP is present in only one known opioid peptide. YP (part of YPG, YPQ, YPH, and YPN) 192 
was present in 92 out of 156 (nearly 60%) opioid peptides present. It is also realised that YP 193 
can be present at amino or carboxyl terminals or in the middle of peptide sequences and may 194 
be followed either by aromatic or non-aromatic amino acids. Majority of opioid peptides have 195 
aromatic amino acid tryptophan (W), phenylalanine (F) or tyrosine (as in YPYY) and had 196 
EC50 value as low as 0.01 µM (YPFGFR, YPFGFRG) and 0.02 µM (YPFGFS, YPFGFK, 197 
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YPFGFG, YPFGFGG, YPFGFKG and YPFGFSG) making these very effective opioids. 198 
Non-aromatic amino acids are also present as isoleucine (I) in YPISL, leucine (L) in YPLG 199 
and YPLSL, serine (S) in YPSYGLN, YPSF and YPS, valine (V) in YPVSL, alanine (A) in 200 
YPASL, threonine (T) in YPTSL and YPTS (Table 2). EC50 values of YPISL, YPVSL and 201 
YPASL were 13.50 µM, 200 µM and 200 µM, respectively. This implies that peptides having 202 
YP structural motif followed by non-aromatic amino acids as predicted in Table 1 (YPG, 203 
YPQ, YPH, YPT, YPS and YPN) may have opioid activity. With limited information 204 
available of EC50 value of the sequences (Table 2), it is also evident that within the search 205 
term, the opioid activity is dependent on chain length of the peptide sequence. For example, 206 
high EC50 values of sequences YYPT (1000µM) and YYP (800µM) are suggestive of their 207 
weak or negligible opioid activity. Similarly, it can also be stated that casein are superior to 208 
gluten as a protein source for the opioid peptides as the EC50 values of peptides containing 209 
YP motif of casomorphin are significantly lower. 210 
 211 
 212 
 213 
  214 
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Table 2 Opioid peptides as predicted by BIOPEP database 215 
Search term – YYP by sequence 
 Name Sequence Molecular 
mass 
EC50 (µM) 
1 gluten A5 exorphin GYYPT 599.61 60 
2 gluten A4 exorphin GYYP 498.50 70 
3  YYPT 542.56 800 
4  YYP 441.45 1000  
5  RYYP 597.64 190  
6  WYYP 627.67 n.d 
7  SYYP 528.53 200  
8  GYYPTS 686.69 72  
Search term – IP by sequence 
1  FGGFTGRIPKLWD
NQ 
1735.95 
n.d 
2  YPFVEPIP 961.10 n.d 
3  YPFPGPIP 887.02 n.d 
4 casoxin C * YIPIQYVLSR 1251.46 
50  
 5 β-casomorphin-11 (60-70) YPFPGPIPNSL 1201.37 10  
Search term – YVP by sequence 
1 fragment of human as1-
casein 
YVPFP 621.71 n.d 
Search term - YP by sequence 
 
1 VV-hemorphin-7 VVYPWTQRF  1194.60 34.3 
2 VV-hemorphin-5 VVYPWTQ  891.43  78.2 
3 oryzatensin* GYPMYPLPR  1092.52  n.d 
4  YPFT  526.23 n.d 
5  LVVYPWTQR  1160.62  n.d 
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6  YPFVEP  750.34 n.d 
7  YPFV  524.25  n.d 
8  YPFVEPIP  960.48  n.d 
9  YPFVE  653.29  n.d 
10 opioid peptide YPFP  522.23  n.d 
11 opioid peptide YPFPGPIP  886.44  n.d 
12 opioid peptide YPF  425.18  n.d 
13 opioid fragment of 
dermorphin 
YAFGYPS  803.33  n.d 
14 opioid fragment of β-
lipotropin β-neoendorphin 
YGGFLRKYP  1099.56  n.d 
15 opioid fragment of β-
lipotropin β/α-
neoendorphin 
YGGFLRKYPK  1227.66  n.d 
16 LVV-hemorphin-7 LVVYPWTQRF  1307.68  29.1 
17 LVV-hemorphin-5 LVVYPWTQ  1004.51  80.5 
18 hemorphin-8 YPWTQRFF  1143.53  4.6 
19 hemorphin-7 YPWTQRF  996.46  2.9 
20 hemorphin-6 YPWTQR  849.40  4.3 
21 hemorphin-5 YPWTQ  693.29  46.3 
22 hemorphin-4 YPWT  565.24  45.2 
23 gluten C exorphin YPISL  591.31  13.5 
24 gluten A5 exorphin GYYPT  599.24  60 
25 gluten A4 exorphin GYYP  498.19  70 
26 gliadin 2 exorphin YPLG  448.22  n.d 
27 casoxin from bovine 
kappa-casein fr: 35-41 
YPSYGLN  812.35  n.d 
28 casoxin (fr.33-38 of 
bovine kappa-casein) * 
SRYPSY  771.34  n.d 
29 Casoxin YPYY  604.24  n.d 
30 β-casomorphin YPSF  512.21  n.d 
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31 β-casomorphin-11 (60-70) YPFPGPIPNSL  1200.60  10 
32 β-casomorphin-7 (60-66) YPFPGPI  789.39 14 
33 β-casomorphin-5 (60-64) YPFPG  579.25  1.1 
34  YPFGFF~  775.35  0.06 
35  YPFGFE~  757.33  0.12 
36  YPFGFW~  814.36  0.09 
37  YPFGFCQ~  756.34  0.08 
38  YPFGFD~  743.31  0.07 
39  YPFGFV~  727.35  0.05 
40  YPFGFS~  715.32  0.02 
41  YPFGFL~  741.37  0.05 
42  YPFGFT~  729.33  0.04 
43  YPFGFI~  741.37  0.04 
44  YPFGFY~  791.35  0.04 
45  YPFGFH~  765.34  0.04 
46  YPFGFM~  759.32  0.03 
47  YPFGFQ~  756.34  0.03 
48  YPFGFP~  725.34  0.03 
49  YPFGFA~  699.32  0.03 
50  YPFGFK~  756.38  0.02 
51  YPFGFG~  685.30  0.02 
52  YPFGFR~  784.38  0.01 
53  YPFGFN~  742.33  0.03 
54  YPFGFGG  743.31  0.02 
55  YPFGFNG  800.33  0.03 
56  YPFGFAG  757.33  0.03 
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57  YPFGFQG  814.35  0.03 
58  YPFGFKG  814.38  0.02 
59  YPFGFMG  817.33  0.03 
60  YPFGFRG  842.39  0.01 
61  YPFGFSG  773.32  0.02 
62  YPFGFDG  801.31  0.07 
63  YPFGFEG  815.33  0.12 
64  YPFGFPG  783.34  0.03 
65  YPFGFCQG  814.35  0.08 
66  YPFGFFG  833.36  0.06 
67  YPFGFVG  785.36  0.05 
68  YPFGFLG  799.37  0.05 
69  YPFGFTG  787.34  0.04 
70  YPFGFIG  799.37  0.04 
71  YPFGFYG  849.35  0.04 
72  YPFGFHG  823.35  0.04 
73  YPFGFWG  872.37  0.09 
74  YYPT  542.22  800 
75  YYP  441.17  1000 
76  YPVSL  577.29  200 
77  YPLSL  591.31  200 
78  YPASL  549.26  n.d 
79  YPTSL  579.27  n.d 
80  YPFSL  625.29  70 
81  RYYP  597.27  190 
82  YPWSL  664.31  70 
16 
 
83  WYYP  627.25  n.d 
84  SYYP  528.21  200 
85  GYYPTS  686.27  72 
86  YPFW~  610.27  n.d 
87  YPFWG  668.28  n.d 
88  YPFF~  571.26  n.d 
89  YPFFG  629.27  n.d 
90 soymorphin-5 YPFVV  623.31  6 
91 soymorphin-6 YPFVVN  737.36  9.2 
92 soymorphin-7 YPFVVNA  808.39  13 
* Opioid antagonist, n.d. = not defined                   216 
 217 
PeptideRanker is a web based application that predicts probability of the peptide to be 218 
bioactive (Mooney et al., 2013). In this study, PeptideRanker was used to rank bioactivity of 219 
peptides as identified from Table 1 and compared to known gluten exorphins (opioid peptides 220 
from wheat) and presented in Table 3. PeptideRanking of known gluten exorphins varied 221 
from 0.55 to 0.96 (Table3) and exorphins A4, B4 and B5 show higher likelihood of 222 
bioactivity based on high ranking than exorphins A5 and C. The ranking for the unknown 11 223 
peptides as identified from Table 1 varied between 0.38 - 0.83. Only 3 out of 11 peptides, 224 
YPG, YYPG and YIPP were ranked > 0.77. These 3 peptides were used for confirmation of 225 
opioid activity.   226 
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Table 3. Ranking of the predicted peptide sequences obtained by PeptideRanker 227 
(bioware.ucd.in) as compared to known exorphins from gluten 228 
Known peptides  Peptide ranking 
GYYPT (exorphin A5) 0.58 
GYYP (exorphin A4) 0.8 
YGGWL (exorphin B5) 0.96 
YGGW (exorphin B4) 0.96 
YPISL (exorphin C) 0.55 
Predicted sequences from Table 1 
YPG 0.83 
YYPG 0.78 
YIPP 0.77 
YVPP 0.52 
YPH 0.59 
YPISP 0.52 
YPTSP 0.41 
YPQ 0.47 
YPS 0.44 
YPN 0.55 
YPT 0.38 
 229 
3.3 Assessment of wheat protein derived peptides for opioid activity 230 
Based on the in silico analysis, peptides YPG, YYPG and YIPP are opioid and should bind to 231 
opioid receptors to exert bioactivity. The activity of these peptides was confirmed by using 232 
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cyclic AMP assay, which is based on inhibition of the adenylate cyclase enzyme. The 233 
decreasing concentration of cAMP within the cells is taken to be an indication of a positive 234 
test and used in determination of activity expressed as EC50 values. All three peptides - YPG, 235 
YYPG and YIPP inhibited production of cAMP in the presence of 10 µM forskolin in cells 236 
expressing µ and κ opioid receptors (Figures 1, 2). Decreases in concentration of cAMP is 237 
graphed against concentration of peptides using GraphPad Prism 7 software and EC50 of the 238 
peptides were calculated from a sigmoid response curve. Calculated EC50 values of all tested 239 
peptides was greater than 1.0 mM for both µ and κ receptors indicating that a high dose of 240 
these peptides is required for them to exert opioid activity. For µ opioid receptor, EC50 values 241 
of YPG, YYPG and YIPP were 5.3 mM, 1.5 mM and 2.9 mM respectively, while for κ opioid 242 
receptor, EC50 values were 1.8 mM, 1.2 mM and 3.2 mM, respectively. For both receptors, 243 
YYPG had the lowest EC50 value, and is more potent opioid peptide than either YPG or YIPP 244 
which can be due to presence of 2 Y residues in the peptide. Also, these peptides have higher 245 
affinity to κ opioid receptors than for µ opioid receptors.  As shown in Table 2, YYP has 246 
EC50 of 1 mM, and presence of glycine (G) at the amino terminal end in GYYP (gluten 247 
exorphin A4) decreased its EC50 value to 70µM making it more effective peptide than YYP. 248 
Presence of non-aromatic amino acid (Threonine, T) at the carboxyl terminal (YYPT) also 249 
decreased its EC50 value to 800 µM but presence of G at the carboxyl terminal (YYPG) did 250 
not decrease EC50 value. Despite of these peptides binding to opioid receptors (µ and , they 251 
are not as effective (higher EC50 values) in their native form and therefore need modification 252 
to improve their binding and agonistic activities. For example, Torino et al., (2010) reported 253 
improvement in opioid activity though modification of native endomorphine-2. Further 254 
research is required to find if these peptides are adsorbed intact or pass the blood brain barrier 255 
(BBB) to make them effective for clinical application. Small size of predicted peptide assures 256 
that these peptides can pass the GI tract (De Noni et al., 2009). Use of D-amino acids, β-257 
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amino acids, various types of synthetic residues and backbone cyclization can improve 258 
stability against enzymatic hydrolysis (Mollica et al., 2013b) and therefore modify their fate 259 
in human system. However, even if these peptides may not be able to pass BBB or absorbed, 260 
they can also stimulate the brain by brain-gut axis (Stefanucci et al., 2016). They are still 261 
worth further investigation for further pharmaceutical development because of their high 262 
selectivity and low toxicity (Garg et al., 2016; Mollica, Pinnen, Azzurra, & Costante, 2013a; 263 
Stefanucci et al., 2016). 264 
 265 
Conclusion 266 
Bioinformatics approach was used in identification of opioid peptides from wheat gluten 267 
proteins. Structural motifs, as particular amino acids or their combinations responsible for 268 
opioid bioactivity were identified. Using tyrosine and proline residues in the peptide 269 
sequences as predictors of opioid peptides, HMW glutenin was found to be the best source of 270 
opioid peptides. It was predicted that eleven peptides from wheat gluten could have opioid 271 
activity, out of which YPG, YYPG and YIPP were selected as these showed higher ranking 272 
of 0.83, 0.78 and 0.77, respectively. The activity of these predicted peptides were determined 273 
using cAMP assay in cell lines expressing opioid receptors. Based on the lowest EC50 value, 274 
YYPG is more potent opioid than YPG or YIPP. The study shows that bioinformatics tools 275 
can assist in screening opioid peptides from gluten proteins. This approach can be a cost 276 
effective for selection and comparison of proteins as source for production of opioid peptides. 277 
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Figure 1.Dose response curves of three peptides (A) and DAMGO (B) against -opioid 289 
receptors based on inhibition of adenylate cyclase as depicted by TRF signal measured at 665 290 
nm. 291 
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Figure 2. Dose response curves of three peptides (A) and dynorphin A (B) against -opioid 298 
receptors based on inhibition of adenylate cyclase as depicted by TRF signal measured at 665 299 
nm.  300 
 301 
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